文献速递脊柱关节炎

EULAR关于银屑病向银屑病关节炎进展可疑临床与影像学特征定义的要点

EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.
PubMed 文献 · Ann Rheum Dis · 2023-06-09

EULAR多学科工作组制定银屑病向银屑病关节炎进展的命名、总体原则和10条要点,提出高危银屑病、亚临床银屑病关节炎和临床银屑病关节炎三阶段命名,强调关节痛和影像学异常是亚临床银屑病关节炎的关键短期预测因素,传统危险因素(银屑病严重度、肥胖、甲受累)可能为长期预测因素。

要点

  • 提出银屑病关节炎前三个阶段命名:高危银屑病、亚临床银屑病关节炎和临床银屑病关节炎。
  • 关节痛和影像学异常是亚临床银屑病关节炎的关键短期预测因素,可用于银屑病关节炎拦截临床试验设计。
  • 传统危险因素(银屑病严重度、肥胖、甲受累)可能为更长期预测因素,对短期转化试验稳健性较低。

核心结论

  • 这些要点有助于定义银屑病患者中可疑进展为银屑病关节炎的临床和影像学特征,有助于识别可能从治疗干预中获益以减轻、延迟或预防银屑病关节炎发生的个体。

研究设计与样本

  • EULAR成立了来自13个欧洲国家的30名成员的多学科工作组,遵循EULAR制定要点(PtC)的标准操作程序。
  • 进行了两项系统文献综述以支持工作组制定要点,并通过名义小组过程提出银屑病关节炎前阶段的命名。

主要发现

  • 提出了银屑病关节炎发病前三个阶段的命名:银屑病关节炎风险较高的银屑病患者、亚临床银屑病关节炎和临床银屑病关节炎。
  • 临床银屑病关节炎阶段定义为银屑病伴相关滑膜炎,可作为评估银屑病向银屑病关节炎转化的临床试验结局指标。
  • 总体原则阐述银屑病关节炎发病时的性质,并强调风湿科与皮肤科合作对银屑病关节炎预防/拦截策略的重要性。
  • 10条要点强调关节痛和影像学异常是亚临床银屑病关节炎的关键要素,可作为银屑病关节炎发生的潜在短期预测因素和设计银屑病关节炎拦截临床试验的有用条目。
  • 银屑病关节炎发生的传统危险因素(即银屑病严重度、肥胖和甲受累)可能代表更长期的疾病预测因素,对于银屑病向银屑病关节炎转化的短期试验稳健性较低。

关键数值与推荐

  • 提出了5条总体原则和10条要点。
  • 提出了银屑病关节炎前三个阶段的命名:银屑病关节炎风险较高的银屑病患者、亚临床银屑病关节炎和临床银屑病关节炎。
  • 临床银屑病关节炎阶段定义为银屑病伴相关滑膜炎。

临床怎么用

  • 这些要点有助于定义银屑病患者中可疑进展为银屑病关节炎的临床和影像学特征。
  • 这些信息有助于识别可能从治疗干预中获益以减轻、延迟或预防银屑病关节炎发生的个体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The transition from psoriasis (PsO) to psoriatic arthritis (PsA) and the early diagnosis of PsA is of considerable scientific and clinical interest for the prevention and interception of PsA. OBJECTIVE: To formulate EULAR points to consider (PtC) for the development of data-driven guidance and consensus for clinical trials and clinical practice in the field of prevention or interception of PsA and for clinical management of people with PsO at risk for PsA development. METHODS: A multidisciplinary EULAR task force of 30 members from 13 European countries was established, and the EULAR standardised operating procedures for development for PtC were followed. Two systematic literature reviews were conducted to support the task force in formulating the PtC. Furthermore, the task force proposed nomenclature for the stages before PsA, through a nominal group process to be used in clinical trials. RESULTS: Nomenclature for the stages preceding PsA onset, 5 overarching principles and 10 PtC were formulated. Nomenclature was proposed for three stages towards PsA development, namely people with PsO at higher risk of PsA, subclinical PsA and clinical PsA. The latter stage was defined as PsO and associated synovitis and it could be used as an outcome measure for clinical trials evaluating the transition from PsO to PsA. The overarching principles address the nature of PsA at its onset and underline the importance of collaboration of rheumatologists and dermatologists for strategies for prevention/interception of PsA. The 10 PtC highlight arthralgia and imaging abnormalities as key elements of subclinical PsA that can be used as potential short-term predictors of PsA development and useful items to design clinical trials for PsA interception. Traditional risk factors for PsA development (ie, PsO severity, obesity and nail involvement) may represent more long-term disease predictors and be less robust for short-term trials concerning the transition from PsO to PsA. CONCLUSION: These PtC are helpful to define the clinical and imaging features of people with PsO suspicious to progress to PsA. This information will be helpful for identification of those who could benefit from a therapeutic intervention to attenuate, delay or prevent PsA development.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023. PMID: 37295926. doi:10.1136/ard-2023-224148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。